Envestnet Portfolio Solutions Inc. Grows Stake in Sanofi (NASDAQ:SNY)

Envestnet Portfolio Solutions Inc. raised its stake in shares of Sanofi (NASDAQ:SNY) by 0.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 112,181 shares of the company’s stock after purchasing an additional 578 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Sanofi were worth $5,411,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Franklin Resources Inc. boosted its stake in shares of Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after purchasing an additional 395,744 shares during the period. Natixis Advisors LLC boosted its position in shares of Sanofi by 1.2% during the fourth quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company’s stock valued at $140,350,000 after buying an additional 35,828 shares during the period. Raymond James Financial Inc. bought a new position in shares of Sanofi during the fourth quarter valued at approximately $135,933,000. JPMorgan Chase & Co. raised its holdings in shares of Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after buying an additional 399,301 shares during the period. Finally, DAVENPORT & Co LLC lifted its stake in shares of Sanofi by 40.7% during the 4th quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after acquiring an additional 664,455 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Price Performance

Shares of SNY stock opened at $59.11 on Wednesday. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $54.03 and a two-hundred day simple moving average of $52.85. The stock has a market capitalization of $150.01 billion, a price-to-earnings ratio of 23.74, a P/E/G ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.